BioSpace News Archive

Natera, Inc. today announced that the company will present new data on its Prospera donor-derived cfDNA (dd-cfDNA) test at the American Transplant Congress (ATC) 2024 taking place June 1–5, 2024.

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps as a potential treatment for age-related conditions, announced the commencement of several significant milestones.

Genprex, Inc. , today announced that its President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, will be providing an overview of the Company’s gene therapies for cancer and diabetes at the upcoming 2024 BIO International Convention.

Enable Biosciences Inc. has been awarded a patent for a cutting-edge method of detecting polyclonal antibodies, marking a significant advancement in diagnostic technologies, particularly in assessing the risk of Type 1 Diabetes (T1D).

RenovoRx, Inc., a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, provided a letter to shareholders from Chief Executive Officer, Shaun Bagai.

Qpex Biopharma, Inc. today announced the exercise of a $10 million option from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, to support the advancement of the company’s antibiotic clinical development program.

CinRx Pharma today announced the closing of a $73 million financing, bringing the total funds raised to $176 million.

ImCheck Therapeutics announced that updated data from its ongoing Phase I/II study EVICTION will be presented in a poster session at the 2024 American Society of Clinical Oncology Annual Meeting being held in Chicago.

Indaptus Therapeutics, Inc. announces that Jeffrey Meckler, Chief Executive Officer, and Roger Waltzman, M.D., M.B.A., Chief Medical Officer, will present a corporate overview at the Jefferies Global Healthcare Conference.

4D Molecular Therapeutics announced that interim data from the Phase 1/2 AEROW clinical trial evaluating aerosolized 4D-710 for treatment of cystic fibrosis lung disease will be presented at the 47th European Cystic Fibrosis Conference, taking place in Glasgow, UK.